The experience of managing patients with anxiety disorders in real clinical practice DOI Creative Commons
P. V. Aronov, G. N. Belskaya, D. I. Cherepakhin

et al.

Meditsinskiy sovet = Medical Council, Journal Year: 2025, Volume and Issue: 22, P. 29 - 36

Published: Jan. 9, 2025

Anxiety disorders (AD) are one of the main health care challenges. Epidemiological studies indicate that ADs occur in 21–30% population over a lifetime. The annual prevalence AD USA is 18.1%, with lifetime 28.2%. In Europe, ranges from 12 to 27%, about 21–30%. Russia, frequency varies 16 31%, more commonly found women and starting at young age. Treating complex due potential negative impact medications on psychophysiological functions. It important select therapy considering its effectiveness, safety, availability, especially after COVID-19 pandemic. Treatment includes psychotherapy psychopharmacotherapy. Normally, neurons limit implement anxiety equilibrium. During anxiety, activity limiting decreases, while implementing increases. goal activate GABAergic serotonergic reduce anxiety. recent years, comprehensive consisting two types drugs has been used treatment AD: SSRIs serotonin tranquilizer called buspirone. Buspirone non-benzodiazepine anxiolytic effective treating AD. fewer side effects compared benzodiazepines. acts receptors 1A-type, providing gradual reduction can also be for monotherapy GAD, augmentation antidepressant therapy, actively applied routine neurological practice. significant therapeutic potential, sufficiently small profile effects, good tolerability. article illustrated by clinical case successful use

Language: Английский

The experience of managing patients with anxiety disorders in real clinical practice DOI Creative Commons
P. V. Aronov, G. N. Belskaya, D. I. Cherepakhin

et al.

Meditsinskiy sovet = Medical Council, Journal Year: 2025, Volume and Issue: 22, P. 29 - 36

Published: Jan. 9, 2025

Anxiety disorders (AD) are one of the main health care challenges. Epidemiological studies indicate that ADs occur in 21–30% population over a lifetime. The annual prevalence AD USA is 18.1%, with lifetime 28.2%. In Europe, ranges from 12 to 27%, about 21–30%. Russia, frequency varies 16 31%, more commonly found women and starting at young age. Treating complex due potential negative impact medications on psychophysiological functions. It important select therapy considering its effectiveness, safety, availability, especially after COVID-19 pandemic. Treatment includes psychotherapy psychopharmacotherapy. Normally, neurons limit implement anxiety equilibrium. During anxiety, activity limiting decreases, while implementing increases. goal activate GABAergic serotonergic reduce anxiety. recent years, comprehensive consisting two types drugs has been used treatment AD: SSRIs serotonin tranquilizer called buspirone. Buspirone non-benzodiazepine anxiolytic effective treating AD. fewer side effects compared benzodiazepines. acts receptors 1A-type, providing gradual reduction can also be for monotherapy GAD, augmentation antidepressant therapy, actively applied routine neurological practice. significant therapeutic potential, sufficiently small profile effects, good tolerability. article illustrated by clinical case successful use

Language: Английский

Citations

0